GLASS LAB · Medical Aesthetics Evidence Index 303 cells · 19,226 papers · 5,969 top-tier evidence

Inflammatory / Specialty · Hidradenitis suppurativa

Botulinum toxin a evidence for Hidradenitis suppurativa

C 47.3 / 100 Supported 3 RCT/meta · 0 clinical/observational · 7 case · 9 total
Early-stage evidence

This is an early evidence stage based mainly on observational studies and case reports. Use it as supplementary reference, and follow your doctor's judgment for treatment decisions.

Grade combines the quantity and quality of the research, while direction is a separate signal showing how the papers assess effectiveness.

Includes meta-analysis/SR Median year 2020 Last 5 years 44% Positive results 33% Negative results 1

Known in Korea as

톡신보톡스제오민디스포트코어톡스주름 보톡스다한증 보톡스디자인 보톡스사각턱 보톡스얼굴전체 톡신

Procedure and brand names vary, but the evidence above applies to the same procedure mechanism.

Key papers

tier1 Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. The Journal of dermatological treatment · 2022 · PMID 33961535

Abstract summary (English) OBJECTIVE: We determined the relative efficacy of non-surgical monotherapies for hidradenitis suppurativa (HS). METHODS: Network meta-analyses were conducted to determine treatments' surface under the cumulative ranking curve (SUCRA) value (i.e. an estimate that ranks efficacy); pairwise comparisons were conducted.

Journal Article, Systematic Review, Network Meta-Analysis

View on PubMed
tier1 Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review. Dermatologic therapy · 2021 · PMID 34796606

Abstract summary (English) Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients.

Journal Article, Systematic Review

View on PubMed
tier1 Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. American journal of clinical dermatology · 2020 · PMID 32761500

Abstract summary (English) BACKGROUND: Botulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile. OBJECTIVE: Our aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS). METHODS: Twenty patients with HS stage I-III disease, according to Hurley's...

Journal Article, Randomized Controlled Trial

View on PubMed
tier0_review Procedural Interventions for Hidradenitis Suppurativa. Dermatologic clinics · 2025 · PMID 40023628

Abstract summary (English) A variety of procedures may be employed for hidradenitis suppurativa, a chronic cutaneous condition that causes abscesses, nodules, and tunnels in skinfold areas. Intralesional steroid or incision and drainage are preferred for acutely inflamed discrete lesions, while deroofing or excision may be pursued for persistent or recurrent areas. Excision and deroofing may target individual lesions or complete regions that...

Journal Article, Review

View on PubMed
tier0_review Botulinum toxin type A for the management of hidradenitis suppurativa. American journal of translational research · 2021 · PMID 35035756

Abstract summary (English) Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease that centers around the hair follicle and occurs as a result of follicular occlusion. HS primarily presents as painful, inflamed lesions that begin during puberty and occur most commonly in areas with numerous apocrine glands. The etiology and pathogenesis of HS involve internal and external factors, including genetic susceptibility,...

Journal Article, Review

View on PubMed
tier0_review Alternative Clinical Indications of Botulinum Toxin. American journal of clinical dermatology · 2020 · PMID 32651806

Abstract summary (English) Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions.

Journal Article, Review

View on PubMed
tier0_review Non-cosmetic dermatological uses of botulinum neurotoxin. Journal of the European Academy of Dermatology and Venereology : JEADV · 2016 · PMID 27421250

Abstract summary (English) Botulinum neurotoxin (BoNT) is renowned for its inhibitory effects on the neuromuscular junction. The evidence for its use in cosmetic dermatology and in non-dermatological indications is well established. We have systemically analysed the evidence for the non-cosmetic dermatological uses of BoNT.

Journal Article, Review

View on PubMed
tier3 Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage. Dermatologic therapy · 2019 · PMID 30693648

Abstract summary (English) Hidradenitis suppurativa is a chronic skin disease with an intense inflammatory activation. It typically affects the intertriginous areas with cysts, fistulae, and scarring extremely painful. Patients suffer from severe psychological impact.

Case Reports, Journal Article

View on PubMed
tier3 Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A. BMJ case reports · 2019 · PMID 30665927

Abstract summary (English) A 41-year-old obese Native American woman presented with hidradenitis suppurativa (HS) after failing all available treatment options. Her HS was more pronounced in the axillary and groin regions (Hurley stage III) and was a major source of her pain and a barrier for home exercise and aquatic therapy. She received a botulinum toxin A injection every 3 months (four times thus far), which has significantly helped...

Case Reports, Journal Article

View on PubMed

Suggested interpretation

Limited evidence

Personalized evidence report

Tell us more about your concern
and the Glass Lab bot will build a personalized report for you.

Based on the Botulinum toxin a · Hidradenitis suppurativa information on this page, we'll email you an evidence summary tailored to your skin condition and treatment stage.

Concerns of interest (select multiple)
Decision stage
← Other indications for the same procedure group  |  Other procedures for the same indication →